

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 19 2002

TECH CENTER 1600/2900
H8
4-22-02
P.2

In re Patent Application of

BRADDOCK et al.

Atty. Ref.: 1430-261

Appln. No. 09/743,516

Group Art Unit: 1632

Filed: January 31, 2001

Examiner: S.D. Priebe

FOR: PHARMACEUTICAL USES OF NAB1 AND NAB2

* * *

REQUEST FOR DRAWING CHANGE

April 18, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

ATTN: OFFICIAL DRAFTSPERSON

Sir:

Submitted herewith are copies of Figures 2 and 3 as originally filed in the above. Correction of the numbering of these figures, as indicated in red on the attached, is requested. This renumbering is consistent with page 30 of the specification.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
Attachments

Figure 2A.
NAB2 trans-repression of endogenous PDGF B production in HVSMC




Figure 3~~X~~. Effect of NAB2 on Egr-1 driven angiogenesis

